© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hill Compares Toxicity Profiles of Current Treatment Regimens in Relapsed CLL
September 24, 2020
During a Case Based Peer Perspectives event Brian T. Hill, MD, PhD, discussed the case of a 53-year-old patients with chronic lymphocytic leukemia.
ACCC President Highlights Oncology Community Response to COVID-19 Pandemic
September 24, 2020
Randall A. Oyer, MD, discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 pandemic.
Morgans Addresses Neuropathic Toxicity in Second-Line Metastatic CRPC
September 24, 2020
Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old male with metastatic castration-resistant prostate cancer.
FDA Grants Fast Track Designation to DKN-01 in Gastric/GEJ Adenocarcinoma
September 24, 2020
The FDA has granted a Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express the protein DKK1, following disease progression on or after prior treatment with fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal receptor growth factor/neu-targeted therapy.
Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates
September 24, 2020
A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.
Moving Chemotherapy Delivery to the Outpatient Setting Results in Substantial Savings
September 23, 2020
The impetus for taking a closer look at cancer drug spending starts with their costs. But the other side of the equation, the revenue coming in, can also be a factor that requires adjusting.
Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer
September 23, 2020
Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Bridging the Gap Between Oncology and Cardiology Takes a Nurse Navigator
September 23, 2020
During the 2020 Association of Community Cancer Centers Virtual National Oncology Conference, a cardio-oncologist and nurse navigator explained the importance of identifying cardiotoxicities in patients with cancer and how to implement a program to help these patients have improved care coordination and experience through employing a nurse navigator
Stage Is Set for Exploring TNBC, HER2-Positive Settings at 38th Annual CFS
September 23, 2020
Delivering evidence-based state-of-the art cancer care in the management of hematologic and solid malignancies is the mainstay of the 38th Annual CFS®: Innovative Cancer Therapy for Tomorrow conference taking place virtually November 4 through 6, 2020.
FDA Grants Priority Review to Crizotinib in Relapsed/Refractory ALK-Positive ALCL
September 23, 2020
The FDA accepted a supplemental New Drug Application for crizotinib and granted it a Priority Review as treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is positive for an ALK alteration.
TIGIT Emerging as Target in Clinical Research Across Cancer Settings
September 23, 2020
Immune checkpoint inhibitors blocking CTLA-4 or PD-1/PD-L1 often provide durable antitumor benefits to certain patients who respond to them; however, the percentage of responders is low, around 15% to 25%.
A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma
September 23, 2020
Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.